Bruno Coudert
机构: Centre Georges Francois Leclerc Dijon France
每年引用次数
引用次数
引用: 17,349
H-指数: 60
I10-指数 : 124
出版物: 426
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
S Guiu , M Gauthier , B Coudert , F Bonnetain
British Journal of Cancer 103 ( 9) 1335 -1342
32
2010
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
Frédérique Végran , Romain Boidot , Bruno Coudert , Pierre Fumoleau
British Journal of Cancer 101 ( 8) 1357 -1364
31
2009
Abstract P1-13-04: Optimal duration of adjuvant chemotherapy for high risk node negative breast cancer patients: 6-year results of the prospective randomized phase III trial PACS 05.
P Kerbrat , B Coudert , B Asselain , C Levy
Cancer Research 72
2
2012
Abstract P5-01-09: Evaluation of Tumor Blood Flow with Dynamic18F-Fluorodeoxyglucose Positron Emission Tomography: Correlation with Microvessel Density
A Cochet , S Pigeonnat , B Buvry , A Berriolo-Riedinger
Cancer Research 70
2010
Abstract P5-01-05: Prognostic Value at 4 Years of FDG PET, after the First Course of Neoadjuvant Chemotherapy in Breast Cancer
O Humbert , A Berriolo-Riedinger , L Arnoud , B Coudert
Cancer Research 70
2010
Abstract P5-01-06: 18[F]-FDG Tumoral Uptake and Metabolic Response after 1 Cycle of Primary Chemotherapy According to Tumoral Phenotype of Breast Cancer
A Berriolo-Riedinger , O Humbert , J-M Riedinger , L Arnoud
Cancer Research 70
2010
Abstract PD07-05: In Situ Immune Response after Neoadjuvant Chemotherapy for Breast Cancer Predicts Survival
S Ladoire , B Coudert , P Fumoleau , L Arnould
Cancer Research 70
2010
P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC.
V Diéras , H Bonnefoi , E Alba , A Awada
Cancer Research 71
2011
Immunophenotype in erythroleukemia secondary to myelodysplastic syndrome [letter; comment]
M Maynadie , F Bailly , RO Casasnovas , B Coudert
Blood 80 ( 4) 1097 -1097
2
1992
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer
C Dittrich , B Coudert , L Paz-Ares , F Caponigro
European Journal of Cancer 39 ( 3) 330 -334
25
2003
PS-030 Off-label use of anticancer drugs: Which benefits and how much?
AS Leromain , C Dimartino , A Schmitt , B Coudert
European Journal of Hospital Pharmacy 23
2016
Abstract P6-08-10: Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort
S Frank , C Tchokothe , M Carton , E Mouret-Fourme
Cancer Research 78
2018
PCN81 COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF ERLOTINIB TREATMENT IN NON0-SMALL-CELL LUNG CANCER:A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)
I Borget , J Cadranel , A Mauguen , B Coudert
Value in Health 13 ( 7)
1
2010
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould , M Gelly , F Penault-Llorca , L Benoit
British Journal of Cancer 94 ( 2) 259 -267
396
2006
Abstract P1-14-21: Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: Development of a specific predictor
C Jankowski , S Guiu , M Cortet , D Hudry
Cancer Research 76
2016
Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials
B Pistilli , T Filleron , C Mazouni , A Zingarello
Cancer Research 78
2018
A phase II trial of radio-chemotherapy with daily carboplatin, after induction chemotherapy (cisplatin and vinorelbine), in locally advanced non-small-cell lung cancer (LANSCLC): final analysis
E Bardet , M Henry-Amar , A Rivière , F Chomy
Lung Cancer 21
1998
Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells.
B Chauffert , D Rey , B Coudert , M Dumas
British Journal of Cancer 56 ( 2) 119 -122
32
1987
Abstract P3-08-07: HER2 positive breast carcinomas: trend in evolution between 1998 and 2008 and relationship with clinico-pathological characteristics in a population based study.
F Beltjens , A Bertaut , S Pigeonnat , N Pouget
Cancer Research 72
2012
Abstract P3-14-13: eIF4E/4EBP1 axis and response to neoadjuvant trastuzumab-based treatment in HER2+ breast cancer – Results of a multicentre French retrospective cohort
F Dalenc , S Le Guellec , L Arnould , B Coudert
Cancer Research 73
2013